← Leaderboards
Maureen Megan O'Brien
University Of Colorado Denver
$344,026
Attributed
$344,026
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $172K · FY2024–25$200K$150K$100K$50K$0
'24
'25
Funding mix
By agency
NIH$344,026 · 1
By mechanism
R50$344,026 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Nina S Kadan-Lottick$5,510,109
- Elizabeth J Shpall$12,617,686
- Douglas K Graham$6,579,169
- Andrew S Kraft$21,224,247
- Philip Reigan$2,271,458
Others in their field
Other Rising Stars on “Adolescent And Young Adult”
- Michael E. Roth · Public Health Institute$8,303,012
- Bhaven Mehta$7,276,100
- Naoko Sasamoto · Brigham And Women'S Hospital$3,002,989
- Leonard R. Henry · Northside Hospital Atlanta$2,953,563
- Sigrun Hallmeyer · Aurora Health Care, Inc.$2,924,481
- Kara N Goss · Ut Southwestern Medical Center$2,418,062
Research focus
Adolescent And Young AdultAntibodiesAntibody-Drug ConjugatesApoptosisBiologyCar T Cell TherapyChildChild CareChild DevelopmentChildhoodChildhood Acute Lymphocytic LeukemiaClinical ResearchClinical TrialsDesignEvaluationFundingGenomicsHigh RiskImmunotherapyImproved OutcomeIndividualized MedicineInterestKinase InhibitorAcute Lymphocytic Leukemia
Grant awards (2)
Pediatric acute lymphoblastic leukemia: Improving outcomes through incorporation of novel targeted therapies into treatment for relapsed and newly diagnosed disease$172,013
R50 · FY2025 · CA · contact PI
Pediatric acute lymphoblastic leukemia: Improving outcomes through incorporation of novel targeted therapies into treatment for relapsed and newly diagnosed disease$172,013
R50 · FY2024 · CA · contact PI